Hyrimoz (adalimumab)

About Sandoz Group

Sandoz is a mission-driven global leader in generics and biosimilars, focused on expanding sustainable access to medicines. Its strategic independence, following the 2023 spin-off, allows for dedicated capital allocation and agile execution in a market driven by patent expiries and cost containment. The company's dual-pillar strategy encompasses a deep pipeline of complex generics and a leading portfolio of biosimilars, supported by world-class development and manufacturing capabilities. With a commercial reach serving approximately 500 million patients annually, Sandoz is positioned to capitalize on significant market opportunities while delivering on its purpose.

Therapeutic Areas

Other Chronic Inflammatory Diseases Drugs